Clinical Trial Update: Oxaliplatin and Topotecan in Advance Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of oxaliplatin and topotecan in advanced or recurrent ovarian cancer was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Ovarian Epithelial Cancer

Drugs mentioned

• Eloxatin (oxaliplatin)
• Hycamtin (Topotecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Ovarian Epithelial Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-11-27